Psychedelic Alpha reports that Resilient has resubmitted its MDMA-for-PTSD application two years after a prior rejection. Here’s what to watch, timelines, and DMV impacts.

A new Psychedelic Alpha podcast surveys D.C.’s psychedelic moment, the FDA’s evolving medical framework, and New Zealand’s MDMA prescribers—here’s why the DMV should care.

A plain‑English guide to where psychedelic-assisted therapy is actually available now, how Oregon, Colorado and New Mexico differ, and what DC, Maryland and Virginia residents should know before making plans.

Dutch officials issued a Red Alert for two-toned Trump-shaped pills that look like ecstasy but contain high-dose PMMA with a slower onset and higher overdose risk.

Journalist Erica Rex urges caution: psychedelic states can open trauma and power imbalances. Here’s what ethical care, safety, and patient-centered practices should look like in the DMV.

DoubleBlind Mag spotlights rising 'pill shaming' in psychedelic spaces. Here’s what it means for people on SSRIs, the early research, and how DMV readers can stay safe.

New research suggests festivals and ceremonial settings may nurture similar trauma relief through community and shared meaning—raising practical lessons for DMV readers.

A close look at new research on psychedelics, authoritarian attitudes, and what an April executive action could mean—plus why DMV cannabis rules are a separate lane.

Clinical trial momentum has regulators eyeing MDMA and psilocybin. Here’s how “abuse potential” factors into rescheduling talks—and what DMV readers should watch.

An executive order in Puerto Rico directs health officials to build a pilot program for ibogaine, psilocybin, and MDMA research, with veterans prioritized for potential clinical trial access.

Psychedelic Alpha reports that two psychiatrists in New Zealand have been cleared to prescribe MDMA for PTSD. Here’s what happened and what DMV readers should know.

Resilient Pharmaceuticals submits a renewed application for MDMA-assisted PTSD therapy, seeking FDA approval without a fresh Phase 3 trial.

An Emory-led consortium is recruiting 800 adults in the US, Canada, and Australia for a first-of-its-kind study on difficulties that persist after psychedelic experiences.